Business
Pfizer’s coronavirus vaccine gets OK from FDA advisers in US – Sydney Morning Herald
The FDA is widely expected to authorise the vaccine, developed with German partner BioNTech SE, for emergency use in the United States within days.
Pfizer has asked that the two-dose vaccine be approved for use in people aged 16 to 85. Several advisory panel members discussed whether 16 and 17-year-olds should be included in the recommendation because the risk to these individuals is low, and the evidence in the trial was scant.
In the end, they voted on the question as put them by the FDA, which included 16 to 17-year-olds. The FDA typically follows the advice of its expert panels, but is not bound to do so.
The panel also discussed concerns…
-
Noosa News19 hours agoSuncorp Stadium upgrades to rival Sydney as seat capacity and infrastructure prioritised
-
Business22 hours agoWhy you should sell CBA, Lynas, and Tabcorp shares today
-
General12 hours agoAustralia Kangaroos lose Xavier Coates and Zac Lomax ahead of rugby league Ashes in England
-
Business21 hours agoDroneShield announces new $13 million counter-drone facility as employees top 400